StockNow
Calendar
Log in
Global Markets

Novo Nordisk (NOVOB DC) Q3 2026 (DKK): Sales 79.2bln (exp. 73.6bln). Raises FY26 Adj. Sales growth outlook to between -2% and 2% at CER (prev. guided fallings up to 6% at CER)

ORIGINAL · NewsquawkNovo Nordisk (NOVOB DC) Q3 2026 (DKK): Sales 79.2bln (exp. 73.6bln). Raises FY26 Adj. Sales growth outlook to between -2% and 2% at CER (prev. guided fallings up to 6% at CER)Read originalHide original

The improved outlook is driven by increased expectations for GLP-1 product sales.

StockNow breaking-news AI analysis

Novo Nordisk reported Q3 sales above expectations and raised FY26 adjusted sales-growth guidance, citing increased expectations for GLP-1 product sales.

News detail

The improved outlook is driven by increased expectations for GLP-1 product sales.

1 stocks
NVONovo-Nordisk A/S$40.16Close

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

[MARKET UPDATE] US equity futures move back into the green, reversing earlier losses following the Democratic sweep; ES was down as much as 1.4% overnight; Bitcoin also reversed earlier losses

Market Analysis

[MARKET ANALYSIS] Democratic trade in full swing, but some AI-sensitive names off worst on PSC results.

NVDAMSFTMETA